Henry Schein (HSIC) Stock Forecast & Price Target

$72.46

+1.22 (+1.71%)

(As of 09/18/2024 ET)

Henry Schein - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 12 Analyst Ratings

Based on 12 Wall Street analysts who have issued ratings for Henry Schein in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 5 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for HSIC.

Consensus Price Target

$77.10
6.40% Upside

High Forecast	$86.00
Average Forecast	$77.10
Low Forecast	$65.00

According to the 12 analysts' twelve-month price targets for Henry Schein, the average price target is $77.10. The highest price target for HSIC is $86.00, while the lowest price target for HSIC is $65.00. The average price target represents a forecasted upside of 6.40% from the current price of $72.46.

Type	Current Forecast 9/19/23 to 9/18/24	1 Month Ago 8/20/23 to 8/19/24	3 Months Ago 6/21/23 to 6/20/24	1 Year Ago 9/19/22 to 9/19/23
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$77.10	$77.10	$81.73	$84.00
Forecasted Upside	6.40% Upside	10.83% Upside	9.68% Upside	6.35% Upside

Trump’s weapon lurks in abandoned America (Ad)

Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…

Go here now to watch my new documentary

HSIC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HSIC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Henry Schein Stock vs. The Competition

Type	Henry Schein	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	8.00% Upside	1,003.17% Upside	7.61% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/12/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$88.00 ➝ $80.00	+17.20%
8/7/2024	UBS Group 4 of 5 stars		Lower Target	Neutral ➝ Neutral	$75.00 ➝ $72.00	+7.29%
8/7/2024	Robert W. Baird 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $82.00	+21.68%
8/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$72.00 ➝ $70.00	+3.92%
8/7/2024	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $82.00	+22.61%
7/22/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
This diversified cannabis pioneer could make huge moves soon (Ad) The cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers. Learn more here.
6/21/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$86.00 ➝ $86.00	+27.37%
3/6/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$74.00 ➝ $81.00	+7.41%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$78.00	-2.33%
11/27/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$75.00	+9.91%
11/14/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$69.00 ➝ $65.00	-3.90%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$96.00	+26.53%
8/7/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$76.00 ➝ $75.00	-1.15%
11/1/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:50 PM ET.

HSIC Forecast - Frequently Asked Questions

What is Henry Schein's forecast for 2024?: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Henry Schein is $77.10, with a high forecast of $86.00 and a low forecast of $65.00.
Should I buy or sell Henry Schein stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last twelve months. There is currently 1 sell rating, 5 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HSIC shares.
Does Henry Schein's stock price have much upside?: According to analysts, Henry Schein's stock has a predicted upside of 10.83% based on their 12-month stock forecasts.
Has Henry Schein been upgraded by Wall Street analysts recently?: Over the previous 90 days, Henry Schein's stock had 2 upgrades by analysts.
What analysts cover Henry Schein?: Henry Schein has been rated by research analysts at Baird R W, Barrington Research, Evercore ISI, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, and UBS Group in the past 90 days.
Do Wall Street analysts like Henry Schein more than its competitors?: Analysts like Henry Schein less than other "medical" companies. The consensus rating score for Henry Schein is 2.50 while the average consensus rating score for "medical" companies is 2.77. Learn more on how HSIC compares to other companies.